•HRES 848 IH 
combat cholera, measles, meningococcal, yellow fever, and 
Ebola, which could also protect Americans in the event 
of an outbreak on United States soil; 
Whereas malaria is one of most long-standing and deadliest 
diseases in Africa, and in 2022, malaria killed an esti-
mated 580,000 children in Africa, 78 percent of whom 
were children under five; 
Whereas Gavi has begun deliveries of new malaria vaccines 
and will expand the program to dozens of countries as 
vaccine supply becomes available; 
Whereas Gavi allocated 18,000,000 doses of the malaria vac-
cine RTS,S in 2023 and 2024, the World Health Organi-
zation estimates that at least 40,000,000 to 60,000,000 
doses will be needed annually by 2026 and 80,000,000 to 
100,000,000 doses will be needed by 2030; 
Whereas Gavi is supporting expanded procurement, access, 
and implementation of new malaria vaccine programs to 
help meet rising demand; 
Whereas data from malaria vaccine trials indicate that these 
vaccines can save one life for every 200 children vac-
cinated, with the potential for significantly impacting 
public health and saving tens of thousands of lives annu-
ally; 
Whereas Gavi supports the strengthening of health systems 
to ensure effective immunization and health services, in-
cluding through the provision of cold chain equipment 
that can also be effectively repurposed for emergency re-
sponse, as was demonstrated during the COVID–19 pan-
demic; 
Whereas, through COVAX, Gavi and global partners deliv-
ered nearly 2,000,000,000 doses of COVID–19 vaccines 
VerDate Sep 11 2014 
01:07 Nov 04, 2025
Jkt 069200
PO 00000
Frm 00004
Fmt 6652
Sfmt 6300
E:\BILLS\HR848.IH
HR848
kjohnson on DSK7ZCZBW3PROD with $$_JOB
•HRES 848 IH 
to 146 economies, and averted an estimated 2,700,000 
deaths in Advance Market Commitment lower-income 
participating economies; 
Whereas Gavi provided additional vaccine support to address 
health service interruptions that occurred during the 
COVID–19 pandemic and contributed to the largest 
backslide in routine childhood immunization in 30 years, 
and focused on the 14,000,000 ‘‘zero-dose’’ children in 
Gavi-supported countries who had not received a single 
vaccine; 
Whereas vaccine programs are widely regarded as high-im-
pact, evidence-based interventions and are among the 
most efficient, cost-effective, and successful health initia-
tives in history, returning over $54 in health and eco-
nomic savings for every $1 invested in Gavi-supported 
countries; 
Whereas the prevention of infectious disease through immuni-
zation in Gavi-eligible countries provides protection and 
health security in the United States by reducing the prev-
alence of infectious diseases and stemming outbreaks at 
their source; 
Whereas United States investment in Gavi complements and 
enhances the effectiveness of other United States invest-
ments in global health, particularly in maternal and child 
health and nutrition; 
Whereas Gavi is committed to working with partners, includ-
ing United States bilateral programs administrated by 
the Department of State and the Centers for Disease 
Control and Prevention (‘‘CDC’’), to ensure children in 
developing nations have access to lifesaving vaccines and 
immunizations; 
VerDate Sep 11 2014 
01:07 Nov 04, 2025
Jkt 069200
PO 00000
Frm 00005
Fmt 6652
Sfmt 6300
E:\BILLS\HR848.IH
HR848
kjohnson on DSK7ZCZBW3PROD with $$_JOB
•HRES 848 IH 
Whereas Gavi’s next strategic cycle will cover the strategic 
period of 2026 to 2030, which will include the expansion 
of Gavi’s malaria program with plans to provide 
50,000,000 doses to children in Gavi-supported countries; 
Whereas the United States has consistently supported the 
goal of saving lives by contributing annually to Gavi to 
meet its projected replenishment and program goals; 
Whereas, with this support and support from other donors, 
Gavi contributed $250,000,000,000 in economic benefits 
in Gavi countries as of 2023, with each $1 invested yield-
ing $54 return on investment; and 
Whereas an increased commitment from the United States 
remains necessary to ensure predictability and stability to 
the vaccine market, to enable strong global health secu-
rity efforts, spur confidence in Gavi-eligible countries, 
and encourage continued innovative vaccine-related ap-
proaches: Now, therefore, be it 
Resolved, That the House of Representatives— 
(1) affirms the continued support of the United 
States Government for the purchase of vaccines for 
low-income countries through Gavi as a cost-effec-
tive, efficient means to reduce mortality and as a 
critical component of meeting the United States goal 
to end preventable child and maternal deaths; 
(2) supports the principles and goals of Gavi 
to— 
(A) introduce and scale up new and rou-
tine immunizations in low-income countries; 
VerDate Sep 11 2014 
01:07 Nov 04, 2025
Jkt 069200
PO 00000
Frm 00006
Fmt 6652
Sfmt 6201
E:\BILLS\HR848.IH
HR848
kjohnson on DSK7ZCZBW3PROD with $$_JOB
•HRES 848 IH 
(B) improve sustainability of immunization 
programs; 
(C) ensure healthy markets for vaccines 
and related products; and 
(D) strengthen health systems to increase 
equity in immunization; 
(3) recognizes that United States Government 
support for Gavi is a critical component to ensuring 
health security in the United States; 
(4) encourages the continued use of Depart-
ment of State maternal and child health and CDC 
global immunization resources to strengthen local 
public health capacity to introduce and sustain new 
and underutilized vaccines supported by Gavi 
through routine immunization systems; 
(5) recognizes the need for multiyear pledges 
from the United States to allow Gavi to maximize its 
impact to provide lifesaving vaccines and to leverage 
contributions from other countries and donors; and 
(6) encourages continued increased commitment 
and investment by the United States Government to 
Gavi in the 2026 to 2030 strategic period in order 
to ensure that lives are protected and saved through 
access to vaccines and immunizations. 
Æ 
VerDate Sep 11 2014 
01:07 Nov 04, 2025
Jkt 069200
PO 00000
Frm 00007
Fmt 6652
Sfmt 6301
E:\BILLS\HR848.IH
HR848
kjohnson on DSK7ZCZBW3PROD with $$_JOB